RecruitingObservational

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

NCT ID: NCT01205815Sponsor: Vanderbilt-Ingram Cancer CenterLast updated: 2025-09-19

Summary

The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

Arms & interventions

OtherTissue and blood collection
Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.

Outcome measures

Primary

Molecular changes in patients' melanoma tissue
Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.
Time frame: at 120 months

Secondary

Improve the time between ordering the test and results entry into medical records
Time frame: 120 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion criteria * Pathologically-proven diagnosis of melanoma. * Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible. Exclusion criteria * Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol. * Any patient unable or unwilling to provide consent.

Study locations (1)

Vanderbitl-Ingram Cancer Center

Nashville, Tennessee

Recruiting

Vanderbilt-Ingram Service for Timely Access · Contact

800-811-8480

Douglas Johnson, MD · Principal Investigator

References

Yan C, Saleh N, Yang J, Nebhan CA, Vilgelm AE, Reddy EP, Roland JT, Johnson DB, Chen SC, Shattuck-Brandt RL, Ayers GD, Richmond A. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Mol Cancer. 2021 Jun 6;20(1):85. doi: 10.1186/s12943-021-01366-y.(PubMed)